Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Pra Health (PRAH)

Pra Health (PRAH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,314,230
  • Shares Outstanding, K 63,961
  • Annual Sales, $ 3,066 M
  • Annual Income, $ 243,020 K
  • 60-Month Beta 1.05
  • Price/Sales 2.09
  • Price/Cash Flow 14.38
  • Price/Book 5.46
Trade PRAH with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate 0.92
  • Number of Estimates 5
  • High Estimate 0.96
  • Low Estimate 0.89
  • Prior Year 1.19
  • Growth Rate Est. (year over year) -22.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
95.84 +1.67%
on 10/30/20
113.41 -14.08%
on 10/14/20
-4.00 (-3.94%)
since 09/30/20
3-Month
94.14 +3.51%
on 09/24/20
113.41 -14.08%
on 10/14/20
-9.31 (-8.72%)
since 07/30/20
52-Week
58.67 +66.08%
on 03/23/20
113.41 -14.08%
on 10/14/20
-1.42 (-1.44%)
since 10/30/19

Most Recent Stories

More News
PRA's World Children's Day Event: Defying Health Care Disparities and Clinical Trial Barriers in Pediatric Populations, Upcoming Webinar Hosted by Xtalks

, /PRNewswire-PRWeb/ -- The PRA Health Sciences Center for Pediatric Clinical Development's second annual acknowledgement of World Children's Day will be celebrated virtually on . World Children's Day...

PRAH : 97.44 (-1.30%)
Global CRO Services Market to Rise Impressively at 9.9% CAGR and Reach US$ 90,926.3 by 2026; forecast to Gain Impetus from Recent Mergers and Acquisitions, says Fortune Business Insights

The global CRO Services Market Size will derive growth from increasing clinical trials in the coming years. According to a report by Fortune Business Insights, titled "Contract Research Organization (CRO)...

ICLR : 180.30 (-1.62%)
PRAH : 97.44 (-1.30%)
PRA Health Sciences to Report Third Quarter 2020 Earnings

EQNX::TICKER_START (NASDAQ:PRAH), EQNX::TICKER_END

PRAH : 97.44 (-1.30%)
PRA Health Sciences dipilih oleh BARDA untuk menjadi ahli Rangkaian Kajian Klinikal yang eksklusifnya

Dengan kontrak baharu, PRA akan membantu Lembaga Penyelidikan dan Pembangunan Lanjutan Bioperubatan (BARDA) dalam pembangunan langkah balas perubatan untuk kesihatan orang awam

PRAH : 97.44 (-1.30%)
PRA Health Sciences selecionada pela BARDA como membro da sua exclusiva Rede de Estudos Clinicos

Com o novo contrato, o PRA ajudara a Biomedical Advanced Research and Development Authority (Autoridade de Pesquisa e Desenvolvimento Biomedico Avancado - BARDA) com o desenvolvimento de contramedidas...

PRAH : 97.44 (-1.30%)
PRA Health Sciences seleccionada por BARDA para formar parte de su Red de Estudios Clinicos exclusiva

Con el nuevo contrato, PRA ayudara a la Autoridad de Investigacion y Desarrollo Avanzado Biomedico (BARDA) en el desarrollo de contramedidas medicas para la salud publica

PRAH : 97.44 (-1.30%)
PRA Health Sciences von BARDA als Mitglied des exklusiven Clinical Studies Network ausgewahlt

Mit dem neuen Vertrag wird PRA die Biomedical Advanced Research and Development Authority (BARDA) bei der Entwicklung medizinischer Massnahmen fur die offentliche Gesundheit unterstutzen

PRAH : 97.44 (-1.30%)
PRA Health Sciencesec"BARDAeEUR %aa...c'a�a'aSc"c(C)c 1/2'c"oecs"ae^a'~

c 3/4a�sae-dega^aOEai 1/4OEPRAadegaaS(C)c"Yc%(C)aOE"ae"~cc"c(C)aa'a�-c�ica�EUR (BARDA)a^a�sa...a...�a"c"YaOE"c--ac-

PRAH : 97.44 (-1.30%)
BARDA eae" PRA Health Sciences a 1/2oececea...adeg^a�eaSc"c(C)c�cuics"ae^a"i

eEUR seae-dega^c'"i 1/4OEPRA adega"aS(C)c"Yc%(C)e"ae"~c'sc"c(C)a'OEe-'c(TM) 1/4ae(C)Yae' (BARDA) a^eea...a...�ei'c"Ye"c(TM)eadegc-

PRAH : 97.44 (-1.30%)
PRA i-iSniei'i-iSn, BARDAeioeeEUR i"deg i"i i-degeu e"niSi'OEi isOEi'ieeioe i"i-

i'e-oe e�"i- 1/2i- e"dege 1/4 PRAeS" eeu ie 1/4i~i- 1/2i'^i�e'i-degeuedegoeedegoeeu(BARDA)i~ i~i-(TM)i eOEEUR i'i^~e' edegoeedegoe iEUR i'

PRAH : 97.44 (-1.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

PRA Health Sciences, Inc. operates as a global contract research organizations providing outsourced clinical development services to the biotechnology and pharmaceutical industries. It offers therapeutic services in the areas of cardio-metabolic, biosimilars, infectious diseases, immunology, neurology...

See More

Key Turning Points

2nd Resistance Point 101.21
1st Resistance Point 99.33
Last Price 97.44
1st Support Level 95.70
2nd Support Level 93.95

See More

52-Week High 113.41
Last Price 97.44
Fibonacci 61.8% 92.50
Fibonacci 50% 86.04
Fibonacci 38.2% 79.58
52-Week Low 58.67

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar